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Abstract: The discovery that nitric oxide (NO) plays crucial roles in mammalian systems has spurred considerable interest in its
translational application. However, the major problem with its application in clinical settings is the high reactivity of NO, which makes
it difficult to supply NO with spatiotemporal accuracy while maintaining its bioactivity. To deliver NO at a specified rate to a preferred
location for a precise period of time is highly demanded. The significant technological advancements in controlled release make it
possible to control NO release at the target site with a sustained release rate and an optimum concentration, and then provide a longer
therapeutic duration of NO. Moreover, biomaterials designed for regenerative applications provide carriers with support structures for
controlled NO releasing. Meanwhile, engineered matrices with controlled NO release have been used as vehicles for stem cell delivery
to enhance cell engraftment and further to improve therapeutic effects of transplanted cells. In this review, we will provide an overview
of controlled NO release materials, as well as the mechanisms of their treatment effects in tissue-repairing processes. Furthermore, the
application of on-demand NO-releasing materials as carriers for stem cell transplantation and the NO-based therapeutic applications in
translational medicine will be discussed.
Key words: Nitric oxide, controlled release, biomaterial, stem cell, regenerative medicine

1. Introduction
Nitric oxide (NO), first identified as a gaseous signaling
molecule and initially called endothelium-derived relaxing
factor (Ignarro et al., 1987), is generated from L-arginine
by constitutive NO synthase (cNOS) or inducible NO
synthase (iNOS) (Marletta, 1993). As a highly reactive
radical, NO has been demonstrated as an essential
molecule that regulates cellular/molecular functions in
mammals and plays vital roles in numerous physiological
systems, such as the cardiovascular, respiratory,
nervous, and immune systems, as well as biological
processes associated with tissue regeneration and cancer
development (Carpenter and Schoenfisch, 2012; Gao et
al., 2013). Deficiency of NO is associated with a number
of pathologies, such as nonhealing chronic wounds,
ischemic diseases, and carcinogenesis (Stone et al., 2012;
Nguyen et al., 2013; Rybinski et al., 2014; Singh and Singh,
2015). Thus, supplying exogenous NO could be a possible
and efficient method for treating these kinds of diseases.
However, an exogenous NO supply is inconvenient,
especially considering its extremely short half-life and the
rapid loss of its bioactivity. Besides, the therapeutic effects
of NO on physiology are concentration-dependent (Diers
et al., 2011; Inoue et al., 2011; Wang et al., 2014), and
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how to sustain NO levels in an optimum range is another
challenge facing NO-based therapy in clinical application.
In response to the need for controlled NO release
for therapeutic application, a chemically modified NO
delivery system that is capable of storing NO in a relatively
inert state and releasing NO in a controlled manner could
be a viable solution (Zhang et al., 2012). In this review,
we will focus on the recent advances in controllable NO
release systems and therapeutic application of NO for
tissue repair and regeneration. Moreover, the therapeutic
mechanisms and theranostic applications of tunable NO
release in translational medicine will be discussed.
2. Controllable NO release systems
Glyceryl trinitrate (GTN), also known as nitroglycerin, has
been widely used for decades to treat heart disease (Agvald
et al., 2002). However, many unwanted side effects, such
as headaches, endothelial dysfunction, and enzymatic
tolerance, caused by the application of GTN have been
reported and uncontrolled NO release is one of the culprits
for these side effects (Ghaffari et al., 2006). Thus, releasing
NO on demand will be of the utmost importance for
developing superior therapies for various diseases caused by
inadequate endogenous NO production. The advancements
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of controlled-release technology have made it possible
to harness NO release at a targeted site with an optimum
concentration-versus-time profile, which provides a longer
therapeutic duration of action and optimizes the therapeutic
effects of NO (Quinn et al., 2015). Numerous controlled
NO-releasing materials have been designed with the aim
of masking undesirable drug properties, which provided
us with useful tools to evaluate the pivotal role of NO in
mammalian systems (Maruhashi et al., 2014).
2.1. Nonenzymatic activated NO release
The prodrug strategy provides an alternative approach to
convert pharmacologically inert derivatives into active
drug molecules in vivo by external stimuli (Kitamura et
al., 2014; Neidrauer et al., 2014). Among these, light- or
humidity-manipulated NO-releasing systems provide
easily adjustable parameters (e.g., wavelength, duration,
and relative intensity) to regulate NO release (Wu and
McGinity, 2000; Sortino, 2012; Bajpai et al., 2015; Chiang
et al., 2015).
A series of NO-releasing substances that could be
photolyzed by light irradiation with wavelengths ranging
from ultraviolet (UV) light (Namiki et al., 1999; Hiramoto
et al., 2001) to visible light (Ostrowski et al., 2012; Hitomi et
al., 2014) to near-infrared (NIR) light (Eroy-Reveles et al.,
2008; Hishikawa et al., 2009) were reported in numerous
studies. Biocompatible polymers and photochemical
NO-releasing complexes were used to form a composite
material, trans-Cr(cyclam)(ONO)2+ (CrONO), which
could release NO for more than 30 h after visible light
irradiation (Mase et al., 2015). Another frequently used
NO donor, S-nitroso-N-acetyl-D penicillamine (SNAP),
was covalently linked to polydimethylsiloxane (PDMS),
which endowed SNAP with the ability of spatiotemporally
controlling NO release (Romanowicz et al., 2013).
Moisture-responsive polymers have been investigated
broadly in the context of drug delivery because of their
fast and ongoing response to humidity and the easy
manipulation for accomplishing precise control of NO
release (Lowe et al., 2012; Liu et al., 2015). Recently,
increasing attention has been paid to the application
of zeolites, three-dimensional microporous crystalline
aluminosilicates, as media for delivering low-molecularweight bioactive substances. With polylactic acid (PLA)
encapsulation, zeolite A had the ability to incorporate
NO under dry conditions and release NO with the only
requirement of moisture (Liu and Balkus, 2009). In
addition, the rate of NO release can be easily handled and
manipulated by altering the PLA fiber porosity. Analogously,
melt-spun ﬁber also had the capability of binding NO
adducts, such as diazeniumdiolates (NONOates) (Lowe et
al., 2012). In order to manipulate NO release, the fiber is
dipped in biodegradable polycaprolactone (PCL) to create
a porous coating on its surface. With the degradation of

the coated materials, the ﬁber complex could replicate the
natural production of NO upon exposure to humidity.
2.2. Enzymatic activated NO release
For enzyme-activated NO generation, NO donors are
blocked by protecting groups to prevent uncontrollable
NO release, and the inactivated donors are often loaded on
a precursor compound that is used as a reservoir or matrix
for both controlled release of NO and delivery of NO (Clas
et al., 2014). Prodrug-activating enzymes are employed to
remove the protecting groups from these parent drugs,
which will lead to the release of active NO.
The most commonly used NO-releasing drugs are
nitrate esters, which can utilize different endogenous
hydrolytic enzymes to achieve bioconversion and NO
release (Napoli and Ignarro, 2003). A series of ester-based
NO-releasing derivatives possessing 1-(pyrrolidin-1-yl)
diazen-1-ium-1,2-diolate or 1-(N,N-dimethylamino)
diazen-1-ium-1,2-diolate moiety were synthesized
(Velázquez et al., 2005). All these compounds could release
NO by incubation with porcine liver esterase in a lower
range (16.3%–19.2%). An improved NO release profile
was observed after incubation with nonspecific esterases
presented in serum (81.6%–93.6% range).
Glycosylation modification is another commonly used
approach to achieve tunable NO release. In this method,
galactose is utilized as a protective moiety to block NO
release from the NO-storing medium; β-galactosidase is
added to remove the protective group, which would finally
be able to initiate NO release in a controlled manner (Figure
1) (Zhao et al., 2013). Two β-galactosidase-responsive
NO-releasing hydrogels were reported recently (Gao et al.,
2013; Zhao et al., 2013). Adding β-glycosidase to remove
the sugar-capping group could lead to controllable NO
release. The rate of NO release could be modulated by finetuning the concentration of β-glycosidase, which could
provide a convenient method to modulate NO release and
maintain the bioavailability of NO.
2.3. Multifunctional NO-releasing system
Recent advances in nanoparticle engineering are creating
new opportunities for the development of multifunctional
nanoparticles for NO delivery. Multifunctional systems
that integrate different functionalities in a coordinated
and organized manner are capable of accommodating a
combination of therapeutic agents with different properties,
such as imaging and specific targeting. Therefore, a targeted
and traceable therapeutic strategy combined with delivery
NO and imaging probes provides a versatile platform that
can potentially enhance the therapeutic efficacy of NO in
regenerative medicine (Hetrick et al., 2009).
2.3.1. Real-time monitoring of controlled NO release
Over the past years, nanotechnology has developed
rapidly and has been employed for disease diagnosis and
treatment. Nanoparticles conjugated with NO-releasing
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Figure 1. The pattern of enzyme-activated nitric oxide (NO) release. The on-demand release of NO is achieved by controlling
the decomposition process of the NO-containing compound (chitosan-NO polymer), which is blocked by a protecting moiety
(galactose). NO release only occurs after β-glycosidase removes the galactose-capping group. Reprinted with permission from
Elsevier (Zhao et al., 2013).

moiety, having both diagnostic and therapeutic functions
in a single integrated system, will improve and expand a
more personalized, customized treatment model based
on molecular-level diagnosis (Chen et al., 2013; Yang et
al., 2013). Several elaborately designed NO-releasing and
imaging nanoparticle products, which could achieve the
objectives of maintaining the potency of NO and further
exploring the mechanism of tissue repair, early diagnosis,
and simultaneous monitoring of therapeutic effect and
timely adjustment of therapy regimen in the context
of tracing NO delivery, have been invented as tools for
theranostic nanomedicine (Rizzo et al., 2013; Ryu et al.,
2014). A chitosan nanosphere, which was exploited as a

318

vehicle of a photoresponsive NO-releasing complex, was
conjugated with fluorescent agents (Tan et al., 2013).
The incorporation of NO-containing materials and NIR
fluorescent quantum dots gave this chitosan-based agent
the capability of releasing NO in a controllable fashion
and monitoring the NO release in situ. The wavelength of
excitation for NO release was much shorter than that of
fluorescent lights emitted from the compound, and thus
no mutual interferences would appear. Researchers further
developed two other compounds with the competence of
effective NO release and excellent properties of optical
imaging, which could be promising agents for theranostics
(Figure 2) (Tan et al., 2013, 2014).
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Figure 2. Dual functional agent with the ability of controlled release and imaging of NO. (a) Synthetic strategy to produce GSH-capped
Ag2S quantum dots (QDs); (b) synthetic strategy and light-triggered NO release mechanism of NIR ﬂuorescent Ag2S QDs@CS-RBS
nanospheres; (c) NIR imaging excited by a 785-nm laser; (d) visible ﬂuorescence imaging excited by 488-nm laser of a nude mouse
at 10 min after subcutaneous injection of Ag2S QDs@CS-RBS nanospheres and CuFL; (e) in a control experiment, a nude mouse was
imaged under irradiation of 488-nm laser at 10 min after subcutaneous injection of CuFL alone. Reprinted with permission from the
Royal Society of Chemistry (Tan et al., 2014).

2.3.2. Site-specific delivery of controlled NO-releasing
agent
A major issue associated with NO donors is to stabilize
and release NO locally and directly in different tissues.
Macromolecules, such as dendrimers, hydrogels, polymers,
and nanoparticles, have been used and exhibit exceptional
potential in directly delivering NO in a controlled spatial
and temporal manner with superior biocompatibility for
pharmacological applications. The NO-donating agent
[Ru(terpy)(bdqi)NO](PF6)3, with the ability of controlled
release of NO upon photoirradiation, was loaded onto
nanoparticles, which endowed the NO donor with an
epidermal targeting effect (Marquele-Oliveira et al., 2010).
Photochemical studies conﬁrmed that light irradiation
could be employed to control NO release and improve
NO concentration in skin. Likewise, the controlled NOreleasing dendrimers, which were capable of selectively
targeting inflamed endothelium, showed significant
therapeutic potential for reducing ischemia/reperfusion
injury (Johnson et al., 2010).
Improving the specificity is a major goal of genedirected enzyme prodrug therapy. Exogenous genes that
encode cell/tissue-speciﬁc enzymes, such as nitroreductase
(Sharma et al., 2013), β-lactamase (Yepuri et al., 2013),
glutathione-S-transferase (GST) (Weyerbrock et al.,
2012), and β-galactosidase (Chen and Zhang, 2013), are
employed to achieve NO release at target sites. A bacterial
biofilm-targeted NO-releasing agent was designed with the

capability of selectively releasing NO upon contact with
enzyme β-lactamase (Yepuri et al., 2013). The locationspecific NO release could minimize the interruption of
NO-associated side effects in normal tissue. Likewise,
an Escherichia coli nitroreductase (NTR)-activated NO
prodrug also had the ability of site-directed release of
NO (Sharma et al., 2013); the derivative of the commonly
used NO donor, diazeniumdiolate (NONOate), could not
release NO until it was metabolized by β-galactosidaseexpressing cells (Chen and Zhang, 2013). Moreover,
O2-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin1-yl]diazen-1-ium-1,2-diolate (JS-K), a site-specific NOreleasing compound that could be activated in glutathione
(GSH)-expressing cells, showed improvement in duration
time and treatment efficacy (Weyerbrock et al., 2012).
3. Mechanism for therapeutic effects of controlled NO
release
NO is involved in diverse processes, such as responding to
oxidative stress and inflammation, controlling blood flow,
and regulating the proliferation and differentiation of cells.
Administration of exogenous NO to elevate NO levels
has been recognized as a strategy for tissue regeneration.
Increasing evidence suggests that NO is a key mediator in
different phases of tissue reparative processes, including
collagen deposition (Han et al., 2012), fibroblast migration
(Han et al., 2012), and angiogenesis (Kazakov et al., 2012;
Most et al., 2013).
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3.1. Promoting angiogenesis
Stimulating angiogenesis is a promising therapeutic strategy
for tissue defects, because nutrients, oxygen, and cytokines
transported by blood vessels are of essential importance
for normal tissue function (Wang et al., 2015; Zhao and Li,
2015). Resuming the blood stream to the damaged area is
a prompt, straightforward, and effective method for tissue
repair. NO and NO-involving signaling pathways could
promote angiogenesis, which was demonstrated as a vital
step in wound healing (Luo and Chen, 2005; Chin et al.,
2011) and ischemic disease recovery (Alkasaki et al., 2004;
Kumar et al., 2007). Supplementation of exogenous NO in
a controlled fashion could modulate the related biological
processes and further promote angiogenesis at the site
of injury (Namkoong et al., 2008). Recently, a study was
performed to compare the proangiogenic potential of six
different NONOate-based NO-releasing agents in a chicken
embryo partial ischemia model (Majumder et al., 2014).
The results showed that different platforms had different
NO-releasing patterns and performed their functions in
different periods of angiogenesis. In this model, spermine
NONOate (SP) exhibited the best angiogenic effect among
these NONOate-based compounds, which highlighted the
necessity of using the most suitable NO-releasing system
during specific phases of tissue regeneration.
3.2. Enhancing efficacy of stem cell-based therapy
Stem cell-based therapy has achieved successful therapeutic
effects in experimental and clinical investigations in
the past few decades, which provides great hope for the
treatment of a wide variety of life-threatening diseases.
However, the low rates of cell engraftment, viability,
and retention limit the application of stem cell therapy
(Li et al., 2009a, 2009b, 2009c; He et al., 2015; Yao et al.,
2015). Because of these obstacles, developing methods for
alleviating cell apoptosis may be of the utmost importance
for stem cell therapy. Moreover, altering stem cell fate (e.g.,
coaxing pluripotent stem cells into committed progenitor
lineages) for therapeutic applications is a feasible and safe
strategy that can minimize the risk of cellular misbehavior
(Li et al., 2008, 2009a, 2009b, 2009c; Su et al., 2011).
NO could participate in regulating cell proliferation,
differentiation, and migration, acting as an important
gaseous signaling molecule (Fuseler and Valarmathi,
2012; Curtis et al., 2014). NO was capable of favoring
tissue regeneration by enhancing self-renewal ability
and inhibiting the maldifferentiation of mesenchymal
progenitors (Buono et al., 2012; Cordani et al., 2014).
Evidence has also been provided to demonstrate that
NO could promote the differentiation of mesenchymal
stem cells (MSCs) into endothelial cells, which was also a
promising strategy for tissue repairing. In a recent study,
bone marrow multipotent progenitor cells (MAPCs) were
cultured with two kinds of NO-releasing agents, NONOate
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and sodium nitroprusside (SNP). Under a sustained NOreleasing environment, increased levels of von Willebrand
factor (vWF) mRNA and protein were found, which
indicated the endothelial differentiation of MAPCs (Chu
et al., 2008).
Utilizing synthetic biomaterials as vehicles for in vivo
transplantation of stem cells has been demonstrated as a
promising strategy for increasing the retention and survival
rate of administrated stem cells. These biomaterials could
not only act as a scaffold for cell anchorage but could also
provide a supportive niche for cell engraftment (Li et
al., 2009a, 2009b, 2009c; He et al., 2015). A recent study
developed a peptide hydrogel, which could release NO in a
controllable manner catalyzed by β-galactosidase, together
with MSCs for myocardial infarction treatment (Yao et al.,
2015). Those results revealed that the NO released from
the hydrogel could significantly enhance the engraftment
and paracrine effect of MSCs. Cotransplantation of MSCs
with NO-releasing hydrogel could lead to better outcomes
of blood vessel reconstruction and heart performance after
myocardial infarction through the NO-activated VEGF/
VEGFR2 pathway in a mouse myocardial infarction model
(Figure 3) (Yao et al., 2015).
3.3. Antimicrobial property of NO
Wound infection remains a serious threat to patients
worldwide. A certain degree of antimicrobial property
of NO has been applied against pathogen invasion
(Hetrick et al., 2009). A probiotic bacteria-based system
that controlled the production of NO gas (gNO) by the
metabolism of lactic acid bacteria in an adhesive gaspermeable membrane was offered to treat dermal wounds
(Jones et al., 2012). In that study, an infected full-thickness
dermal wound model was used to evaluate the preclinical
efficacy of this novel patch. Over 21 days of therapy, wound
closure in the gNO-producing patch-treated groups was
significantly increased based on the antimicrobial activity
of NO.
4. Controlled NO release for tissue regeneration
Mounting evidence indicates that an appropriate
concentration of NO at the injury site is favorable for
tissue repair, while deficient endogenous NO production
could hamper the recovery process (Oplander et al., 2012).
Exogenous supplementation of NO could be the best way
to cope with the problem of NO deficiency. Curative effects
showed that localized and well-timed NO replenishing
in an on-demand manner could be a superior strategy
to promote tissue repair compared to spontaneous NO
release.
4.1. NO therapy for cardiovascular diseases
Cardiovascular disease (CVD) remains the leading cause
of death and morbidity in the world (He et al., 2015; Yao
et al., 2015; Zhao and Li, 2015). The nonsurgical treatment
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Figure 3. NapFF-NO hydrogel enhances the therapeutic effect of AD-MSCs for myocardial infraction. Encapsulation of AD-MSCs
by NapFF-NO hydrogel could prevent transplanted cells effusing from injection positions. NO molecule released from NapFF-NO
hydrogel catalyzed by β-galactosidase had the ability to facilitate angiogenic cytokine secretion of AD-MSCs, resulting in promoting
angiogenesis, AD-MSC survival, and cardiac function. Reprinted with permission from Elsevier (Yao et al., 2015).

of cardiac therapy has been proven to be a low-risk and
high-efficiency treatment option for cardiac patients by
restoring oxygenated blood flow back to the heart and
other organs of the body (Fang et al., 2013). Extensive
experimental and clinical investigations have revealed
the association between vascular NO and cardiovascular
disease (Rochette et al., 2013). Reduced NO production
and impaired NO bioavailability are the common causes
of cardiovascular diseases.
In cardiovascular disease therapy, NO is recognized as
a unique reactive modulator involved in vascular function
during tissue ischemia. The NO donor SNAP has showed
cardioprotective effects. However, a high dosage of SNAP
was required to obtain this therapeutic effect, which was
toxic to cells. To tackle this issue, SNAP was conjugated
with polyamidoamine dendrimers with large drug
payloads. Minimized dosage of SNAP and a better curative
efficacy for reducing infarct size and ischemia/reperfusion

injury were obtained by the triggering of GSH (Johnson
et al., 2010). Additionally, conjugation to chemically
modified micromolecules could confer the capability of
tissue selectivity to NO donors, which has demonstrated
good therapeutic effect in the ischemia/reperfusion injury
model. A new type of S-nitrosothiol-based macromolecular
NO-releasing complex, mannosylated (Man)-poly SNObovine serum albumin (BSA) and galactosylated (Gal)poly SNO-BS, was designed and synthesized (Katsumi
et al., 2009). These complexes made it possible to target
NO delivery in the compromised tissue and prolong the
retention of NO donors in the systemic circulation. NO
released from these macromolecules restored proper
circulation after a period of restricted blood ﬂow.
After myocardial infarction, apoptotic and necrotic
cardiomyocytes are progressively replaced by fibroblastlike cells, which lead to the impairment of cardiac
function. Stem cell therapy is a new therapeutic
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approach for repopulating damaged myocardium via cell
transplantation (Li et al., 2009a, 2009b, 2009c; Yao et al.,
2015). Despite this, the beneficial effects of transplanted
cells are limited due to low retention of these cells during
the early posttransplantation period (Du et al., 2015; He et
al., 2015). Transplantation of stem cells in biomaterials to
produce better retention and engraftment in the infarcted
heart has been widely reported. Transplantation MSCs with
controllable NO-releasing hydrogel exhibited relatively
high effects on heart function improvement, which could
be attributed to the hydrogel-enhanced cell engraftment
and survival and the NO-promoted angiogenesis and
blood vessel reconstruction in ischemic myocardium (Yao
et al., 2015).
4.2. Tunable release of NO for wound healing
Patients suffering from chronic wounds and impaired
healing conditions will become even more burdensome
in both human health and economic terms (Eming et
al., 2014). Innovative therapies for treating unhealed
wounds or for speeding up the repair of acute wounds
and maximal restoration of tissue function are needed.
Topical application of therapeutic agents combined with
controlled NO release have provided a safe, efficient,
and feasible remedy for treating these lesions without
interrupting normal tissues (Oplander et al., 2013).
The therapeutic effects exhibited by NO are in
connection with its concentration (Burke et al., 2013),
release time, and cell types (Fleissner and Thum, 2011;
Krause et al., 2011). It is absolutely vital to deliver NO to
the target area in a well-contained manner, for excessive
amounts of NO could pose a greater risk of injury
to certain tissues. Nanoparticle-based drug delivery
systems have been broadly used as a promising method
to improve the efficacy of existing drugs with the ability
to achieve increased therapeutic duration, enhanced
bioavailability, and controlled drug release (Probst et al.,
2013). Conjugating NO donors to nanoparticles (NONPs) could significantly increase the therapeutic effect of
NO. In different treatment groups, skin-injured mice were
respectively treated with NO-NPs, nanoparticles without
NO, and DETA NONOate (Blecher et al., 2012). In the
treated groups, the wound area in NO-NP-treated mice
decreased by 29.4% compared to 1.9% in nanoparticletreated mice and 2.3% in DETA NONOate-treated mice,
which showed higher therapeutic efficiency of controlled
NO release compared to the group with spontaneous NO
release. Likewise, the treatment effect of another kind of
NO-NP during the wound repair process was evaluated
(Han et al., 2012). The NO level was increased in the NONP-treated group compared to the nanoparticle-treated
group and the untreated control group. A high wound
closure rate was obtained and complete wound closure was
achieved only in the NO-NP-treated group.
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Ordinary bandage dressings are widely used in wound
management with certain advantages. Combined with NOreleasing technology, several fabrics and bandages have
been applied in medical practice and exhibited a greater
potency to accelerate wound healing. Comparing topical
application of NO-releasing ﬁlms with an extremely short
period, erythema disappeared and an increasing rate of
blood ﬂow was obtained (Marcilli and de Oliveira, 2014).
Likewise, applying electrospinning technology, humiditysensitive NO-releasing bandages and dressings were
developed and assessed (Lowe et al., 2015). The wound
healing rate of the NO-treated groups was significantly
faster than that of the control group. Additionally, the
average capillary density in the NO-treated group was
about 60% higher than that of the control group.
NO-releasing sutures hold promise in treating injury
located in deep tissue. PCL-coated melt-spun acrylonitrilebased sutures could release NO continually (Lowe et al.,
2014). NO could be released from the sutures after they
were exposed to moist environments. With PCL coating,
the NO release process could be prolonged, which could
prevent infection and promote wound healing.
4.3. Controlled NO release to injured tendon and muscle
Tendon and muscle injuries are common, which result
in billions of dollars in health care expenses. NO is a
function-preserving and repair-stimulating mediator in
injury and disease, which has been demonstrated to have
great therapeutic potency in both tendinopathies and
muscle injuries, for it is remarkably effective for preserving
function and stimulating repair of the injured tissue
(Murrell et al., 2008; De Palma et al., 2014).
Addition of NO through nitric oxide-paracetamol
could enhance tendon healing by improving collagen
content and organization in damaged tendons (Murrell et
al., 2008). In a cGMP-dependent pathway, NO was capable
of stimulating the proliferation of satellite cells, which are
critical to sustain muscle regeneration during numerous
rounds of damage (Kuang et al., 2008). It has been
demonstrated that the enhanced self-renewal ability of
satellite cells induced by treatment with the NO-donating
drug molsidomine was sufﬁcient to increase the number of
satellite cells during repetitive acute and chronic damages
and favored muscle regeneration (Buono et al., 2012). NObased therapy also exhibited the ability of enhancing the
regenerative potential of the damaged muscle by inhibiting
the maldifferentiation of mesenchymal ﬁbroadipogenic
progenitors into adipocytes (Cordani et al., 2014).
5. Summary
The current existing controllable NO-releasing systems
have gradually demonstrated their superiority, such as the
ease of manipulation, site specificity, longer duration of
NO release, excellent biocompatibility, and reduced side
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effect profiles. Based on the understanding of therapeutic
mechanisms, preliminary evaluations have showed
that these NO-releasing agents have great potential for
regenerative medicine and tissue engineering. Controlling
the extent, rate, and time of NO release can be a very
practical approach to optimize its performance. Moreover,
the development of high-quality NO controlled-release
formulations provides optimism for NO-releasing
platforms for regenerative therapy.
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